Belgium-based cell therapy and regenerative medicine developer Promethera Biosciences closed €10m ($11m) in a series C extension on Friday that included Société Régionale d’Investissement de Wallonie (SRIW).

SRIW, the regional investment group backed by the government of Wallonia, participated alongside conglomerate Mitsui, pharmaceutical firm Boehringer Ingelheim and tissue engineering researcher LifeLiver.

Cell Innovation Partners, Vesalius Biocapital, Fund+ and SMS Investments also took part in the round, as did Mitsubishi UFJ Capital, the venture capital arm of Mitsubishi UFJ Financial Group.